- Human pathology

Home > A. Molecular pathology > MT1G


16q13 MIM.156353 HGNC:7399 Entrez:4495

Tuesday 23 February 2010

metallothionein 1G

GeneRIFs (February 2010)

- p16INK4A, DAPK1, PTEN and MT1G genes were not frequently methylated in the stage I non-small cell lung cancer in China.

- MT1G acts as a tumor suppressor gene in hepatocellular carcinoma

- Promoter methylation and differential gene expression of five markers: COL1A2, NPM2, HSPB6, DDIT4L and MT1G were validated by sequencing of bisulfite-modified DNA and real-time reverse transcriptase PCR, respectively.

- Using a panel of four genes (AHRR, p16INK4a, MT1G, and CLDN3) resulted in sensitivity and specificity of 50% and 68%, respectively and may have utility for early detection of esophageal squamous dysplasia and early ESCC.

- MT1G is hypermethylated in renal cell carcinoma.

- Induction of the hMT1G promoter by VEGF and heavy metals occurs through the utilization of different transcription factors.

- Eight MT genes were up-regulated after treatment of T-ALL cells with 0.15 and 1.5 microg/mL of metal ores. Heavy metal binding activity.

- Loss of metallothionein 1G function due to hypermethylation of its promoter leads to athogenesis of papillary thyroid carcinoma

- MT1G hypermethylation: a potential prognostic marker for hepatoblastoma. (20032811)


- MT1G hypermethylation: a potential prognostic marker for hepatoblastoma. Sakamoto LH, de Camargo B, Cajaiba M, Soares FA, Vettore AL. Pediatr Res. 2009 Dec 21. PMID: 20032811